Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus

Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second‐line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression‐free survival rate remains short. We report one patient with mRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Tendo, Koie, Takuya, Horiguchi, Hirotaka, Tokui, Noriko, Narita, Satoshi, Ohyama, Chikara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715416/
https://www.ncbi.nlm.nih.gov/pubmed/29225833
http://dx.doi.org/10.1002/ccr3.1181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715416/
https://www.ncbi.nlm.nih.gov/pubmed/29225833
http://dx.doi.org/10.1002/ccr3.1181

Ejemplares similares